Clinical Trials in Myocardial Infarction and Coronary Heart Disease

  • Lewis H. Kuller


The relationship between thrombosis, coronary atherosclerosis and myocardial infarction has evolved over many years.1 There has been considerable controversy about the specific role of thrombosis in both myocardial infarction and sudden death,2 as well as the importance of vessel wall, platelet interactions in the evolution of atherosclerosis. The interaction of vessel wall injury, platelets and hyperlipidemia in the development of the atherosclerotic plaque and complications seems to be a most plausible hypothesis.


Myocardial Infarction Acute Myocardial Infarction Sudden Death Angina Pectoris Anticoagulation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Gorlin, V. Fester and J. A. Ambrose, Anatomic-physiologic links between acute coronary syndromes. (Editorial) Circulation 74:6 (1986).PubMedCrossRefGoogle Scholar
  2. 2.
    M.J. Davies and A. Thomas, and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 310:1137 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Maseri, S. Chierchia and G. Davies, Pathophysiology of coronary occlusion in acute infarction. Circulation 73:233 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    J. E. Saffitz, R. C. Fredrickson and W. C. Roberts, Relation of size of transmural acute myocardial infarct to mode of death, interval between infarction and death and frequency coronary arterial thrombosis. Am J Cardiol 57:1249 (1986).PubMedCrossRefGoogle Scholar
  5. 5.
    L. A. Harker, Clinical trial evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation 73:206 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    E. R. Eichner, Platelets, carotids, and coronaries: Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets. Am J Med 77:513 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    T. L. Simon, J. H. Ware and J. M. Stengle, Clinical trials of thrombolytic agents in myocardial infarction. Ann Intern Med 79:712 (1973).PubMedCrossRefGoogle Scholar
  8. 8.
    G. S. Reeder and R. E. Vlietstra, Coronary angioplasty: 1986. Mod Concepts Cardiovasc Dis 55:49 (1986).Google Scholar
  9. 9.
    T. W. Meade, M. Brozovic, R.R. Chakrabarti, et al., Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 2:533 (1986).PubMedCrossRefGoogle Scholar
  10. 10.
    L. Wilhelmsen, K. Svardsudd, K. Korsan-Bengtsen, et al., Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501 (1984).PubMedCrossRefGoogle Scholar
  11. 11.
    G. J. Miller, J. C. Martin, J. Webster, et al., Association between dietary fat intake and plasma factor VII coagulant activity — A predictor of cardiovascular mortality. Atherosclerosis 60:269 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    T. W. Meade, D. J. Howarth, Y. Stirling, et al., Fibrinopeptide A and sudden death. Lancet 2:607 (1984).PubMedCrossRefGoogle Scholar
  13. 13.
    T. W. Meade, R. Chakrabarti, A. P. Haines, et al., Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1:153 (1979).PubMedCrossRefGoogle Scholar
  14. 14.
    H. L. J. Markowe, M. G. Marmot, M. J. Shipley, et al., Fibrinogen: a possible link between social class and coronary heart disease. Br Med J 291:1312 (1985).CrossRefGoogle Scholar
  15. 15.
    C. R. M. Hay, A. P. Durber and R. Saynor, Effect of fish oil on platelet kinetics in patients with ischaemic heart disease. Lancet 1:1269 (1982).PubMedCrossRefGoogle Scholar
  16. 16.
    L. H. Kuller, J. A. Perper, W. S. Dai, et al., Sudden death and the decline in coronary heart disease mortality. J Chron Dis (1986) (In Press).Google Scholar
  17. 17.
    V. Rissanen, Sudden coronary death and coronary artery disease. Cardiology 64:289 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    J. A. Perper, L. H. Kuller and M. Cooper, Arteriosclerosis of coronary arteries in sudden, unexpected deaths. Circulation 52(Suppl 3):27 (1975).Google Scholar
  19. 19.
    J. Stamler, D. Wentworth and J. Neaton. Middle-aged American men at very low risk of coronary death; six-year findings on the 356, 222 screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Presented at the X World Congress of Cardiology, Washington, D.C., September (1986).Google Scholar
  20. 20.
    D. J. Gordon, L. G. Ekelund, J. M. Karon, et al., Predictive value of the exercise tolerance test for mortality in North American men: The Lipid Research Clinics Mortality Follow-up Study. Circulation 74:252 (1986).PubMedCrossRefGoogle Scholar
  21. 21.
    P. M. Rautaharju, R. J. Prineas, W. J. Eifler, et al., Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial Experience. J Am Coll Cardiol 8:1 (1986).PubMedCrossRefGoogle Scholar
  22. 22.
    L. H. Kuller, Natural History of Coronary Heart Disease, in: Heart Disease and Rehabilitation, Second Edition, M. L. Pollock and D. H. Schmidt, eds., John Wiley and Sons, Inc., New York, New York, 1986.Google Scholar
  23. 23.
    The Multicenter Postinfarction Research Group, Risk stratification and survival after myocardial infarction. N Engl J Med 309:331 (1983).CrossRefGoogle Scholar
  24. 24.
    G. S. May, K. A. Eberlein, C. D. Furberg, et al., Secondary prevention after myocardial infarction: A review of long-term trials. Prog Cardiovasc Dis 24:331 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    T. C. Chalmers, R. J. Matta, H. Smith and A. M. Kunzler, Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 297:1091 (1977).PubMedCrossRefGoogle Scholar
  26. 26.
    R. H. Gifford and A. R. Feinstein, A criticue of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med 280:351 (1969).PubMedCrossRefGoogle Scholar
  27. 27.
    E. Genton and A. G. G. Turpie, Anticoagulant therapy following acute myocardial infarction: Part II. Antithrombotic therapy in acute myocardial infarction. Mod Concepts Cardiovasc Dis 52:49 (1983).Google Scholar
  28. 28.
    Gruppo Italiano Per Los Studio Delia Streptochinasi Nell’Infarto Miocardico (GISSI), Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397 (1986).Google Scholar
  29. 29.
    The I.S.A.M. Study Group, A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 314:1465 (1986).CrossRefGoogle Scholar
  30. 30.
    D. O. Williams, J. Borer, E. Braunwald, et al., Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73:338 (1986).PubMedCrossRefGoogle Scholar
  31. 31.
    S. Yusuf, R. Peto, J. Lewis, et al., Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27:335 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Lewis H. Kuller
    • 1
  1. 1.Graduate School of Public Health, Department of EpidemiologyUniversity of PittsburghPittsburghUSA

Personalised recommendations